Recent advances in the discovery and development of quinolones and analogs as antitumor agents.
Compounds that interact with DNA or microtubules by multiple mechanisms and cause diverse cytotoxic lesions are potential targets for anticancer drug development. Accordingly, a relatively new approach to the rational design of antitumor agents is based on the quinolone class of antibacterials. Their mechanism of antibacterial action involves inhibition of DNA gyrase, and numerous new quinolones do exhibit antitumor activity. Thus, these new quinolone structures display a novel mode of action for the quinolone class as antitumor agents. The potential for quinolones to be used as topoisomerase II inhibitors, as well as antimitotic agents, is reviewed with a focus on recent discoveries and development of antitumor quinolones, especially related work in the author's laboratory.
Xia
Y
Y
Natural Products Laboratory, Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Yang
Z Y
ZY
Morris-Natschke
S L
SL
Lee
K H
KH
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D015363:Quinolones / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D015363:Quinolones; D059005:Topoisomerase II Inhibitors